RT Journal Article SR Electronic T1 Detection of SARS-CoV-2 in Different Human Biofluids Using the Loop-Mediated Isothermal Amplification Assay: A Prospective Diagnostic Study in Fortaleza, Brazil JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.01.23.22269711 DO 10.1101/2022.01.23.22269711 A1 Marco Clementino A1 Karene Ferreira Cavalcante A1 Vania Angelica Feitosa Viana A1 Dayara de Oliveira Silva A1 Caroline Rebouças Damasceno A1 Jessica Fernandes de Souza A1 Rafhaella Nogueira Della Guardia Gondim A1 Daniel Macedo de Melo Jorge A1 Lyvia Maria Vasconcelos Carneiro Magalhães A1 Érico Antônio Gomes de Arruda A1 Roberto da Justa Pires Neto A1 Melissa Soares Medeiros A1 Armênio Aguiar dos Santos A1 Pedro Jorge Caldas Magalhães A1 Liana Perdigão Mello A1 Eurico Arruda A1 Aldo Ângelo Moreira Lima A1 Alexandre Havt YR 2022 UL http://medrxiv.org/content/early/2022/01/24/2022.01.23.22269711.abstract AB We adopted the reverse transcriptase - loop mediated isothermal amplification (RT-LAMP) to detect SARS-Cov-2 in patient samples. Two primer sets for genes N and Orf1ab were designed to detect SARS-CoV-2, and one primer set was designed to detect the human gene Actin. We collected prospective 138 nasopharyngeal swabs, 70 oropharyngeal swabs, 69 saliva, and 68 mouth saline wash samples from patients suspected to have severe acute respiratory syndrome (SARS) caused by SARS-CoV-2 to test the RT-LAMP in comparison with the golden standard technique RT-qPCR. Accuracy of diagnosis using both primers, N5 and Orf9, was evaluated. Sensitivity and specificity for diagnosis was 96% (95% CI 87-99) and 85% (95% CI 76-91) in 138 samples, respectively. Accurate diagnosis results were obtained only in nasopharyngeal swab processed via extraction kit. Accurate and rapid diagnosis could aid COVID-19 pandemic management by identifying, isolating, and treating patients rapidly.HighlightsNew nucleic acid amplification test for the diagnosis of SARS-CoV-2 using the RT-LAMPN5 primer set showed mutations in strains of interest, such as the gamma strain (P.1) of SARS-CoV-2When evaluated in combination N5 and Orf9 primer sets maintained high sensitivity and specificityCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [grant number 403548/2020-9] and Coordenacao de Aperfeicoamento Pessoal de Nivel Superior - Programa Institucional de Internacionalizacao (CAPES-PRINT) [grant number 88887.593075/2020-00].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This proposal was approved by the National Ethical Review Board on 06/10/2020 with the code CAAE 33460220.7.0000.5045. Data collected from the research participants were kept confidential.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsCOVID-19coronavirus disease 2019FBSfetal bovine serumHMPVhuman metapneumovirusNAATnucleic acid amplification testRT-LAMPreverse transcription loop-mediated isothermal amplificationPBSphosphate-buffered salineRT-qPCRquantitative reverse transcription-polymerase chain reactionRV-16rhinovirus serotype 16SARS-CoV-2severe acute respiratory syndrome-coronavirus 2TCID50median tissue culture infective doseTPCKtosylsulfonyl phenylalanyl chloromethyl ketone